Literature DB >> 9530545

Butenafine.

W McNeely1, C M Spencer.   

Abstract

Butenafine is a new antifungal agent with primary fungicidal activity against dermatophytes such as Trichophyton mentagrophytes, Microsporum canis and Trichophyton rubrum which cause tinea infections. 14C-labelled butenafine (approximately 30 micrograms/g tissue) was found within guinea-pig dorsal skin 24 hours after topical application. Most of the drug was distributed into the epidermis including the horny layer. Small amounts were found in the dermis, probably transported via sebaceous glands and hair follicles. In vitro, the minimum concentration that completely inhibited growth of dermatophytes (MIC) and the minimum fungicidal concentrations (MFC) for butenafine against T. mentagrophytes and M. canis were similar (0.012 to 0.05 mg/L) and were 4 to 130 times lower than those for naftifine, tolnaftate, clotrimazole and bifonazole. It also has greater activity against T. rubrum, M. gypseum and Epidermophyton floccosum when compared with naftifine, tolnaftate and clotrimazole; comparisons with bifonazole against these strains were not available. Assessment after 1 week's treatment in patients with tinea pedis revealed that mycological cure rates were greater in those who received twice-daily butenafine for 1 week or once-daily butenafine for 4 weeks than in placebo recipients. Mycological and overall cure rates were either further increased or maintained up to 5 weeks after treatment cessation compared with end-of-treatment values. In patients with tinea cruris or tinea corporis who received once-daily butenafine 1% for 2 weeks, the mycological and overall cure rates continued to increase for up to 4 weeks after treatment cessation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9530545     DOI: 10.2165/00003495-199855030-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent.

Authors:  D L Greer; J Weiss; D A Rodriguez; A A Hebert; J M Swinehart
Journal:  J Am Acad Dermatol       Date:  1997-08       Impact factor: 11.527

2.  Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream.

Authors:  E Tschen; B Elewski; D C Gorsulowsky; D M Pariser
Journal:  J Am Acad Dermatol       Date:  1997-02       Impact factor: 11.527

3.  One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial.

Authors:  R Savin; R L De Villez; B Elewski; S Hong; T Jones; N Lowe; A Lucky; B Reyes; D Stewart; I Willis
Journal:  J Am Acad Dermatol       Date:  1997-02       Impact factor: 11.527

4.  Update on topical therapy for superficial fungal infections: focus on butenafine.

Authors:  R B Odom
Journal:  J Am Acad Dermatol       Date:  1997-02       Impact factor: 11.527

5.  [Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent].

Authors:  T Maeda; M Takase; A Ishibashi; T Yamamoto; K Sasaki; T Arika; M Yokoo; K Amemiya
Journal:  Yakugaku Zasshi       Date:  1991-02       Impact factor: 0.302

Review 6.  Mechanisms of action of systemic antifungal agents.

Authors:  B E Elewski
Journal:  J Am Acad Dermatol       Date:  1993-05       Impact factor: 11.527

7.  Two mechanisms of butenafine action in Candida albicans.

Authors:  W Iwatani; T Arika; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 8.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

9.  Anti-Trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs.

Authors:  T Arika; T Hase; M Yokoo
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs.

Authors:  T Arika; M Yokoo; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more
  6 in total

1.  Experimental and conformational analyses of interactions between butenafine and lipids.

Authors:  M P Mingeot-Leclercq; X Gallet; C Flore; F Van Bambeke; J Peuvot; R Brasseur
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Fenticonazole nitrate loaded trans-novasomes for effective management of tinea corporis: design characterization, in silico study, and exploratory clinical appraisal.

Authors:  Rofida Albash; Maha H Ragaie; Mahmoud A El Hassab; Radwan El-Haggar; Wagdy M Eldehna; Sara T Al-Rashood; Shaimaa Mosallam
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: comparative clinical study.

Authors:  Caroline Lamie; Enas Elmowafy; Maha H Ragaie; Dalia A Attia; Nahed D Mortada
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2% sertaconazole and topical 1% butenafine in tinea infections of skin.

Authors:  Saket J Thaker; Dimple S Mehta; Hiral A Shah; Jayendra N Dave; Shailesh G Mundhava
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

5.  A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield's ointment + oral fluconazole versus topical 1% butenafine in tinea infections of skin.

Authors:  Saket J Thaker; Dimple S Mehta; Hiral A Shah; Jayendra N Dave; Kunjan M Kikani
Journal:  Indian J Pharmacol       Date:  2013 Nov-Dec       Impact factor: 1.200

6.  Topical clotrimazole cream for the treatment of tinea cruris: A retrospective study.

Authors:  Dan Zhao; Bing Chen; Ying-Ting Wang; Chuan-Hua Jiao
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.